Online inquiry

IVTScrip™ mRNA-Anti-ALB&IL17A, M-1095(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10707MR)

This product GTTS-WQ10707MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets ALB&IL17A gene. The antibody can be applied in Psoriasis research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized; Vicugna pacos (alpaca)
RefSeq NM_000477.7; NM_002190.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 213; 3605
UniProt ID P02768; Q16552
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ALB&IL17A, M-1095(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ10707MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5968MR IVTScrip™ mRNA-Anti-IL6, CLLB8(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CLLB8
GTTS-WQ8375MR IVTScrip™ mRNA-Anti-TACSTD2, aTROP2S7(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA aTROP2S7
GTTS-WQ8216MR IVTScrip™ mRNA-Anti-SLC39A6, hLIV22(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA hLIV22
GTTS-WQ313MR IVTScrip™ mRNA-Anti-IGF1R, 19D12(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 19D12
GTTS-WQ9196MR IVTScrip™ mRNA-Anti-FOLR1, IMGN853(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IMGN853
GTTS-WQ4932MR IVTScrip™ mRNA-Anti-GP, c13C6-FR1-N(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA c13C6-FR1-N
GTTS-WQ14948MR IVTScrip™ mRNA-Anti-PDCD1, SHR-1210(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SHR-1210
GTTS-WQ5174MR IVTScrip™ mRNA-Anti-IL13, CAT-354(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CAT-354
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW